Comparison of neoadjuvant chemotherapy and bladder-preserving chemoradiation in patients with non-metastatic, muscle-invasive bladder cancer: A single-center experience

Basit Öğe Kaydı
dc.authorscopusid57205580317
dc.authorscopusid57193238894
dc.authorscopusid55987915300
dc.authorscopusid56891371400
dc.authorscopusid57207826720
dc.authorscopusid57223350887
dc.authorscopusid57204363676
dc.contributor.authorGökyer A.
dc.contributor.authorKüçükarda A.
dc.contributor.authorKöstek O.
dc.contributor.authorHacioğlu M.B.
dc.contributor.authorİşsever K.
dc.contributor.authorÖzler T.
dc.contributor.authorÇevik G.
dc.date.accessioned2024-06-12T10:26:03Z
dc.date.available2024-06-12T10:26:03Z
dc.date.issued2020
dc.description.abstractObjective: Approaches for curative treatment of muscle-invasive bladder cancer include radical cystectomy after neoadjuvant chemotherapy and chemoradiotherapy. We compared the results of these treatment modalities in our clinic. Material and Methods: A total of 43 patients with muscle-invasive bladder cancer, who underwent front-line cystectomy or received neoadjuvant chemoradiotherapy between 2010 and 2018, were compared retrospectively. Results: Twenty patients received definitive chemoradiotherapy, and 23 patients underwent surgery (cystectomy) after neoadjuvant treatment. The median age was 68 years, and 86% of the patients were male. The median age was higher in the chemoradiotherapy group, and the number of patients with an ECOG performance score above 2 was significantly higher in this group. In patients who underwent surgery after neoadjuvant treatment, median disease-free survival was 17.1 months (CI: 6.1-27.9) and overall survival (OS) was 22.2 months (CI: 10.3-34.1), whereas disease-free survival was 12.5 months (CI: 9.7-15.3) (p=0.93). The OS was 12.7 months (CI:1.0-33.9) (p=0.74) in the group receiving definitive chemoradiotherapy. Survival was significantly longer (p=0.03) in patients who were treated with radical cystectomy, and pathological downstaging (T1 tumor and below) was achieved. In addition, the male gender, smoking above 40 pack-years, and alcohol remarkably reduced the OS. Conclusion: The OS and disease-free survival were similar between patients in the chemoradiotherapy and surgery groups. In contrast, patients with ECOG performance score below 2 and pathological downstaging after neoadjuvant chemotherapy had prolonged survival. © 2020 by Turkish Society of Medical Oncology.en_US
dc.identifier.doi10.37047/jos.2020-77532
dc.identifier.endpage146en_US
dc.identifier.issn2452-3364
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85105689025en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage141en_US
dc.identifier.trdizinid423342en_US
dc.identifier.urihttps://doi.org/10.37047/jos.2020-77532
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/423342
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16652
dc.identifier.volume6en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofJournal of Oncological Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemoradiotherapy; Cystectomy; Urinary Bladder Neoplasmsen_US
dc.subjectCarboplatin; Cisplatin; Adjuvant Chemoradiotherapy; Adult; Aged; Alcohol Consumption; Article; Cancer Free Survival; Cancer Staging; Cigarette Smoking; Clinical Article; Clinical Outcome; Comparative Effectiveness; Controlled Study; Cystectomy; Female; Human; Male; Median Survival Time; Middle Aged; Monotherapy; Muscle Invasive Bladder Cancer; Neoadjuvant Chemotherapy; Overall Survival; Scoring System; Sex Differenceen_US
dc.titleComparison of neoadjuvant chemotherapy and bladder-preserving chemoradiation in patients with non-metastatic, muscle-invasive bladder cancer: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu